267 related articles for article (PubMed ID: 30816547)
21. A computational method for drug repositioning using publicly available gene expression data.
Shabana KM; Abdul Nazeer KA; Pradhan M; Palakal M
BMC Bioinformatics; 2015; 16 Suppl 17(Suppl 17):S5. PubMed ID: 26679199
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
23. Paradoxical Pro-angiogenic Effect of Low-Dose Ellipticine Identified by In Silico Drug Repurposing.
Oh J; Lee HH; Jeong Y; Yoon S; An HJ; Baek M; Kim DK; Lee S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445773
[TBL] [Abstract][Full Text] [Related]
24. An Application of Computational Drug Repurposing Based on Transcriptomic Signatures.
Karatzas E; Kolios G; Spyrou GM
Methods Mol Biol; 2019; 1903():149-177. PubMed ID: 30547441
[TBL] [Abstract][Full Text] [Related]
25. Computational Drug-repositioning Approach Identifying Sirolimus as a Potential Therapeutic Option for Inflammatory Dilated Cardiomyopathy.
Shibata K; Endo T; Kuribayashi Y
Drug Res (Stuttg); 2019 Oct; 69(10):565-571. PubMed ID: 31238376
[TBL] [Abstract][Full Text] [Related]
26. Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
Chudasama P; Renner M; Straub M; Mughal SS; Hutter B; Kosaloglu Z; Schweßinger R; Scheffler M; Alldinger I; Schimmack S; Persigehl T; Kobe C; Jäger D; von Kalle C; Schirmacher P; Beckhaus MK; Wolf S; Heining C; Gröschel S; Wolf J; Brors B; Weichert W; Glimm H; Scholl C; Mechtersheimer G; Specht K; Fröhling S
Clin Cancer Res; 2017 Feb; 23(4):962-973. PubMed ID: 27535980
[No Abstract] [Full Text] [Related]
27. Impact of S100A8 expression on kidney cancer progression and molecular docking studies for kidney cancer therapeutics.
Mirza Z; Schulten HJ; Farsi HM; Al-Maghrabi JA; Gari MA; Chaudhary AG; Abuzenadah AM; Al-Qahtani MH; Karim S
Anticancer Res; 2014 Apr; 34(4):1873-84. PubMed ID: 24692722
[TBL] [Abstract][Full Text] [Related]
28. RNA-Sequencing, Connectivity Mapping, and Molecular Docking to Investigate Ligand-Protein Binding for Potential Drug Candidates for the Treatment of Wilms Tumor.
Luo JY; Yan SB; Chen G; Chen P; Liang SW; Xu QQ; Gu JH; Huang ZG; Qin LT; Lu HP; Mo WJ; Luo YG; Chen JB
Med Sci Monit; 2020 Mar; 26():e920725. PubMed ID: 32214060
[TBL] [Abstract][Full Text] [Related]
29. DeSigN: connecting gene expression with therapeutics for drug repurposing and development.
Lee BK; Tiong KH; Chang JK; Liew CS; Abdul Rahman ZA; Tan AC; Khang TF; Cheong SC
BMC Genomics; 2017 Jan; 18(Suppl 1):934. PubMed ID: 28198666
[TBL] [Abstract][Full Text] [Related]
30. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.
Rahman MR; Islam T; Gov E; Turanli B; Gulfidan G; Shahjaman M; Banu NA; Mollah MNH; Arga KY; Moni MA
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30658502
[TBL] [Abstract][Full Text] [Related]
31. Molecular docking and machine learning analysis of Abemaciclib in colon cancer.
Liñares-Blanco J; Munteanu CR; Pazos A; Fernandez-Lozano C
BMC Mol Cell Biol; 2020 Jul; 21(1):52. PubMed ID: 32640984
[TBL] [Abstract][Full Text] [Related]
32. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.
Cao Y; Lu X; Wang J; Zhang H; Liu Z; Xu S; Wang T; Ning S; Xiao B; Wang L
Int J Mol Med; 2017 Feb; 39(2):268-278. PubMed ID: 28075449
[TBL] [Abstract][Full Text] [Related]
33. Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8
Chen H; Chen Y; Liu H; Que Y; Zhang X; Zheng F
Front Immunol; 2018; 9():1179. PubMed ID: 29896199
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
[TBL] [Abstract][Full Text] [Related]
35. Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation.
Sohraby F; Bagheri M; Aryapour H
Methods Mol Biol; 2019; 1903():23-43. PubMed ID: 30547434
[TBL] [Abstract][Full Text] [Related]
36. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles.
Kim IW; Jang H; Kim JH; Kim MG; Kim S; Oh JM
Sci Rep; 2019 Feb; 9(1):2660. PubMed ID: 30804389
[TBL] [Abstract][Full Text] [Related]
37. Prediction of Novel Drugs for Hepatocellular Carcinoma Based on Multi-Source Random Walk.
Yu L; Su R; Wang B; Zhang L; Zou Y; Zhang J; Gao L
IEEE/ACM Trans Comput Biol Bioinform; 2017; 14(4):966-977. PubMed ID: 27076463
[TBL] [Abstract][Full Text] [Related]
38. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis.
Toro-Domínguez D; Carmona-Sáez P; Alarcón-Riquelme ME
Arthritis Res Ther; 2017 Mar; 19(1):54. PubMed ID: 28284231
[TBL] [Abstract][Full Text] [Related]
39. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J
Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580
[TBL] [Abstract][Full Text] [Related]
40. Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data.
Fortney K; Griesman J; Kotlyar M; Pastrello C; Angeli M; Sound-Tsao M; Jurisica I
PLoS Comput Biol; 2015 Mar; 11(3):e1004068. PubMed ID: 25786242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
